Latest publications

The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis. Spekhorst LS, De Graaf M, Van der Rijst LP, Zuithoff NPA, Schweizer RC, Kamsteeg M et al. Clin Transl Allergy 2023 Jan; 13(1):e12219

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate-to-severe ocular surface disease. Achten R, Thijs J, Van der Wal M, Van Luijk C, Van Luin M, El Amrani M et al. Clin Transl Allergy 2023 Jan; 13(1):e12221

Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry. Kamphuis E, Boesjes CM, Loman L, Bakker DS, Poelhekken M, Zuithoff NPA et al. Pediatr Allergy Immunol 2022 Dec; 33(12):e13887

Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients. Achten R, Thijs J, Van Luijk C, Knol E, Delemarre E, De Graaf M et al. Clin Exp Allergy 2022 Dec 22

Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. Bieber T, Katoh N, Simpson EL, De Bruin-Weller M, Thaçi D, Torrelo A et al. J Dermatolog Treat 2023 Dec; 34(1):2161812

Melanomas in children and adolescents: Clinicopathologic features and survival outcomes. El Sharouni MA, Rawson RV, Potter AJ, Paver EC, Wilmott JS, Witkamp AJ et al. J Am Acad Dermatol 2022 Dec 09

Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey. Augustin M, Costanzo A, Pink A, Seneschal J, Schuster C, Mert C et al. Acta Derm Venereol 2022 Dec 07; 102:adv00830

Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma. Hermans MM, Rietman AB, Schappin R, De Laat PCJ, Mendels EJ, Breur JMPJ et al. Eur J Pediatr 2023 Feb; 182(2):757-767

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry. Boesjes CM, Kamphuis E, Zuithoff NPA, Bakker DS, Loman L, Spekhorst LS et al. Acta Derm Venereol 2022 Nov 24; 102:adv00820

Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients. Spekhorst LS, Van der Rijst LP, De Graaf M, Van Megen M, Zuithoff NPA, Knulst AC et al. Allergy 2022 Nov 24

A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis. Van de Meeberg MM, Hebing RCF, Nurmohamed MT, Fidder HH, Heymans MW, Bouma G et al. Br J Clin Pharmacol 2023 Jan; 89(1):61-79

Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry. Spekhorst LS, De Graaf M, Loeff F, Zuithoff NPA, Bakker D, Boesjes CM et al. JAMA Dermatol 2022 Dec 01; 158(12):1409-1413

Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Simpson EL, Merola JF, Silverberg JI, Reich K, Warren RB, Staumont-Sallé D et al. Br J Dermatol 2022 Dec; 187(6):888-899

Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry. Spekhorst LS, De Graaf M, Zuithoff NPA, Van den Reek JMPA, Kamsteeg M, Boesjes CM et al. JAMA Dermatol 2022 Sep 01; 158(9):1048-1056

Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study. Ter Haar ELM, Thomas SE, Van den Reek JMPA, Otero ME, Njoo MD, Ossenkoppele PM et al. Drugs Aging 2022 Sep; 39(9):715-727